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Prostate cancer is the second most common cause of death from
cancer in men in the UK and the age-specific mortality from the
disease is increasing. Prospective studies (using nested case–control
design), including one previously carried out by us, have shown that
the measurement of serum prostate-specific antigen (PSA) is an
effective screening test for prostate cancer in healthy men
(Ballentine Carter et al, 1992; Helzlsouer et al, 1992; Stenman et al,
1994; Gann et al, 1995; Whittemore et al, 1995; Parkes et al, 1995;
Jacobsen et al, 1996).
PSA occurs in the blood mainly in a complex with a1-anti-
chymotrypsin (PSA-ACT) and partly in its free form. Assays for
(total) PSA detect both these forms, including the Hybritech assay
used in our previous publication (Parkes et al, 1995) and the
Wallac assay that we used in the study described in this paper
which has been carried out on the same data set. The data of
Stenman et al (1991) in symptomatic men suggested that measure-
ment of PSA-ACT alone was more discriminatory than measure-
ment of total PSA as a test for prostate cancer. Stenman et al
(1994) also suggest that, in asymptomatic men with raised PSA
concentrations, measurement of the ratio PSA-ACT to total PSA
may improve discrimination between men who were subsequently
diagnosed with prostate cancer and men who were not. Several
subsequent studies suggested that use of the ratio will reduce the
false-positive rate (that is, the proportion of men who do not
develop prostate cancer with a positive test result, which is one
minus specificity) in symptomatic men with raised PSA levels, at
the expense of a small reduction in the detection rate (proportion
of men developing prostate cancer with a positive test result, sensi-
tivity), as summarized by Woodrum et al (1998). To clarify the
issue in asymptomatic men using a large data set, we decided to
measure free and total PSA in our stored serum samples in men
who developed prostate cancer and in men who did not, and esti-
mate the performance of screening using the different forms of
PSA alone and in combination.
METHODS
The study was based on the same four cohorts used in our previous
publication (Parkes et al, 1995). In total there were 49 261 healthy
men: the British United Provident Association (BUPA) study
(London, UK) (Wald et al, 1987), the CLUE study in Washington
County, Maryland (US) (Helzlsouer et al, 1992), the North Karelia
project (Puska et al, 1979) and the Social Insurance Institution
Mobile Clinic Health Survey (Knekt et al, 1988) (both in Finland),
as previously described. Serum samples taken from healthy men
on recruitment were frozen and stored, and 265 of these men
(cases) with serum samples available subsequently developed
clinical prostate cancer, or died of prostate cancer. A nested
case–control study design was used. Controls were men from the
same study who had not developed prostate cancer at the end of
follow-up. Five controls were selected per case, except in the
CLUE study (two controls selected per case), making a total of
1055. Controls were matched with each case for age (within 1
year), duration of storage of the sample (collected within the same
calendar year) and the number of freeze–thaw cycles. Cases were
followed up for a median of 17.5 years and controls for 17.4 years
(range 10–20 years).
Total PSA was previously measured in the cases and controls
using the Tandem-R PSA radioimmuno-assay kits (Hybritech)
assay (Parkes et al, 1995). This study is based on 247 of the 265
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remained available for further assays. Samples from each case and
control were retrieved from storage and assayed for total PSA and
free PSA at the Wolfson Institute of Preventive Medicine, London,
UK, without knowledge of which samples were from cases and
which from controls. The Wallac PROSTATUS PSA free/total kit
was used – an automatic immunoassay that uses the 1235 Auto
DELFIA system for the simultaneous determination of total PSA
and free PSA in serum. PSA-ACT was calculated by subtracting
the free PSA concentration from the total PSA concentration.
Total PSA levels measured by the Wallac kit agreed very closely
with measurements previously obtained using the Hybritech kit
(correlation coefficient = 0.99); only the results using the Wallac
assay are presented here.
The median concentrations of total PSA and free PSA in the
controls were not significantly associated with duration of storage
or number of freeze–thaw ‘cycles’. Total PSA, free PSA and PSA-
ACT all increased with age (the increases per 10 years of age were
42% (95% confidence interval (CI) 28–57%), 51% (95% CI
37–67%) and 42% (95% CI 29–56%) respectively). To allow for
this increase with age and for variations between centres, each
concentration was expressed as a multiple of the median (MOM)
for a given centre and age. The medians were derived from the
controls using a weighted log-linear regression of median concen-
trations on age and centre. The median concentrations and median
ages, in 5-year age groups, were taken for each centre, and
weighted by the number of men in each group. A positive
screening result was defined as a concentration of total PSA, PSA-
ACT or free PSA that exceeded a specified MOM cut-off level.
The performance of screening was assessed by fitting Gaussian
distributions to the distributions of log10 MOM total PSA, free
PSA, and PSA-ACT. A bivariate log Gaussian model was used to
determine likelihood ratios for free PSA and PSA-ACT combined
after confirming the range of values over which the data fitted log
Gaussian distributions. This likelihood ratio was then applied to
the overall risk of developing prostate cancer in the population, to
give an estimated risk of developing prostate cancer for that indi-
vidual man, which ignored the influence of age on his risk. Men
with a risk estimate above a specified cut-off value were desig-
nated screen positive. The method has been published previously
(Wald et al, 1988; Royston and Thomson, 1992).
RESULTS
Figure 1 shows the MOM values of free PSA plotted against 
PSA-ACT MOM values in cases and controls. They were highly
correlated (correlation coefficient 0.85 in controls, P < 0.0001).
Because the correlation was high, one cannot have a substantially
better screening performance than the other and both together can
only make a modest improvement to the use of either alone.
Table 1 shows the median, 10th and 90th centiles of MOM total
PSA, free PSA, and PSA-ACT in men who presented with clinical
prostate cancer (cases) and in men who did not (controls). This
shows that PSA-ACT, total PSA and free PSA were all high in
cases (even in those who did not present until more than 10 years
later).
Table 2 shows the detection and false-positive rates according to
the different PSA measurements, different cut-off levels and
different lengths of follow-up. The detection and false-positive
rates were derived from fitting the Gaussian distribution to the
distribution of MOM values. Probability plots of the three PSA
measurements were reasonably linear (see Figure 2), showing that
the three measurements were all approximately Gaussian. The
plots also illustrate the extent of the separation in values between
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Figure 1 Free PSA MOM values against PSA-ACT MOM values (adjusted
for age and centre) in 953 men who did not develop prostate cancer (controls
represented by open circles) and in 94 men who developed clinical prostate
cancer within 10 years (solid circles)
Table 1 Median (10th and 90th centiles) in multiples of the median (MOM) in controls of total PSA, free PSA
and PSA-ACT in men who developed clinical prostate cancer (cases) according to time to diagnosis, and in
men who did not (controls)
Cases: time to
presentation 
(years ) No. of men Total PSA Free PSA PSA-ACTa
<3 14 25 (8.3–53) 9.1 (2.9–20) 28 (8.8–61)
3–5.9 27 4.7 (1.9–26) 3.4 (1.4–14) 4.8 (1.7–31)
6–9.9 53 4.2 (1.1–9.4) 2.1 (0.81–6.3) 4.4 (1.1–10)
³10 153 1.9 (0.61–6.0) 1.5 (0.52–4.6) 2.0 (0.62–6.5)
All cases 247 2.6 (0.75–11) 1.8 (0.63–6.8) 2.8 (0.73–12)
Controls 953 0.98 (0.37–3.1) 1.00 (0.39–2.8) 0.98 (0.33–3.2)
aCalculated by subtracting free PSA from total PSA and then converting into a MOM value.cases and controls. The false-positive rates at specified MOM cut-
off levels were similar for the different tests. Total PSA and PSA-
ACT were comparable in screening performance, and either was
better than free PSA. Differences in the estimates in Table 2
compared with our earlier paper (Parkes et al, 1995) are small and
due to the differences in the sample numbers and the fact that the
present results were based on the model while the earlier ones
were based on directly observed numbers.
Table 3 shows the detection rates according to specified false-
positive rates, again based on the Gaussian distribution. This
shows that free PSA and PSA-ACT combined give the highest
detection rates, up to 2 percentage points higher for given false-
positive rates than using PSA-ACT alone, and up to 4 percentage
points higher than total PSA. Because PSA-ACT and free PSA are
so highly correlated the two together are only modestly better in
discriminating between affected and unaffected men than the
better of the two (PSA-ACT) used alone.
Tables 5 and 6 give details of the cut-off levels used and the
parameters of the distributions which will permit further statistical
analysis of the results. Table 7 is a comparison of the detection
rates based on the use of the Gaussian model with those directly
observed by counting how many men had MOM values above
specified levels. This shows good agreement between the two sets
of estimates.
DISCUSSION
Our results show that, were screening for prostate cancer shown to
be worthwhile, there is only a small advantage in using free PSA
and PSA-ACT combined appropriately rather than PSA-ACT alone
or total PSA alone. For example, at a false-positive rate of 1%, the
detection rate for cancers presenting within 3 years was 97% for
free PSA and PSA-ACT combined, 96% for PSA-ACT and 95%
for total PSA. The corresponding estimates for cancers presenting
within 6 years were 56%, 54% and 52% respectively. If the cost of
measuring PSA-ACT and free PSA is similar to measuring total
PSA alone or PSA-ACT alone it may be worth taking advantage of
the small increase in detection, but not otherwise.
We examined the value of measuring the ratio of PSA-ACT to
total PSA in men with high serum total PSA levels (above 2
MOMs and above 4 MOMs), as previously recommended by
Stenman et al (1991, 1994). Only men with both total PSA MOM
values above the cut-off and a high ratio of PSA-ACT to total PSA
were designated screen positive. This gave a comparable screening
PSA screening for future prostate cancer 733
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Table 2 Detection rates and false-positive rate of screening for clinical prostate cancer by measurement of total PSA, free PSA, and PSA-ACT standardized
for age and centre, according to cut-off level and interval between blood sampling and diagnosis of prostate cancer, based on Gaussian distributions of risk
factors
Detection rate
False-positive
rate (n = 953) Within 3 years (n = 14) Within 6 years (n = 41) Within 10 years (n = 94)
Cut-off level 
MOMa Total PSA Free PSA PSA-ACT Total PSA Free PSA PSA-ACT Total PSA Free PSA PSA-ACT Total PSA Free PSA PSA-ACT
³4 5.8 5.0 5.7 99.6 87 99.7 74 56 75 56 40 58
³6 2.2 1.7 2.1 98 72 98 61 39 63 42 24 44
³8 1.0 0.7 0.9 95 57 96 51 27 53 32 16 35
³12 0.3 0.2 0.2 85 35 88 37 15 39 21 8 23
aMOM = multiples of the median value in men of the same age and at the same centre who do not develop clinical prostate cancer.
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Figure 2 Probability plot of total PSA (A), free PSA (B) and PSA-ACT (C) in
multiples of the normal median (MOM) (log scale). Solid dots represent men
who developed clinical prostate cancer within 10 years and open dots
represent men who did notperformance for a given false-positive rate, compared with using
total PSA alone.
Following previous practice, we expressed the concentration in
three forms of PSA in MOMs for men who did not develop
prostate cancer who were of the same age and from the same
centre. This conveniently allows for the increase in concentrations
with age, and differences that can arise from centre to centre. Table
4 shows the observed and regressed (or expected) medians
according to age and centre, which illustrates the importance of
correcting for these effects. The regressed median concentrations
correspond to MOM values of one.
Analysis of our data, based on the variation in duration of storage
of the samples (between 15 and 22 years), shows that total PSA is
stable but free PSA declines at about 2% per year (P = 0.06).
Previous published studies also show a decline in free PSA during
frozen storage (Woodrum et al, 1996, 1998; Wu and Stephenson,
1997). There is an additional small loss of PSA when the blood
sample is stored at room temperature before centrifugation, of
0.5–1.0% per h (Piironen et al, 1996; Woodrum et al, 1996) and
when serum is stored before freezing, of 3–4% per day (Woodrum et
al, 1996). After freezing, freeze–thaw cycles do not cause detectable
loss of free PSA concentration (Piironen et al, 1996; Woodrum et al,
1996). The average free PSA concentration in the control samples in
our study (mean 0.27 mg L–1, standard deviation 0.34 mg L–1) was
about 30% lower than values in men in the same age range based on
measurements in fresh samples (Orstein et al, 1997; Lein et al, 1998)
and this is consistent with the estimated 2% per year loss during
frozen storage and the small loss before freezing.
This loss of free PSA will not affect our estimates of screening
performance. There is no reason to expect that the proportionate
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Table 3 Detection rate of prostate cancer corresponding to specified false-positive rates for total PSA, free PSA, PSA-ACT,  and for PSA-ACT and free PSA
combined, standardized for age and centre, according to interval between blood sampling and diagnosis of prostate cancer. Performance determined by
Gaussian modelling of the distributions
Detection rate
Within 3 years (n = 14) Within 6 years (n = 41) Within 10 years (n = 94)
PSA-ACT and  PSA-ACT and PSA-ACT and
False-positive Total Free PSA- free PSA Total  Free  PSA- free PSA Total Free PSA- free PSA
rate (%) PSA PSA ACT combined PSA PSA ACT combined PSA PSA ACT combined
5.0 99.4 87 99.6 99.7 72 56 73 75 53 39 56 57
2.0 98 74 98 98.9 60 41 62 64 41 26 44 45
1.0 95 63 96 97 52 32 54 56 33 19 36 37
0.5 91 52 93 95 44 24 47 49 26 14 29 31
Table 4 Median concentrations of total PSA, free PSA, and PSA-ACT in men who did not develop clinical prostate cancer
(controls) according to age and centre
Men aged 50  Men aged 45–54  Men aged 60  Men aged 55–64
Regressed median† Observed median Regressed median† Observed median
Total PSA
BUPA 0.73 0.71 1.04 1.06
CLUE 0.61 0.70 0.87 0.85
North Karelia 0.60 0.59 0.86 0.78
SIIMCHS 0.62 0.64 0.88 0.82
Free PSA
BUPA 0.11 0.10 0.17 0.17
CLUE 0.15 0.17 0.22 0.20
North Karelia 0.13 0.14 0.19 0.17
SIIMCHS 0.14 0.15 0.22 0.20
PSA-ACT
BUPA 0.61 0.58 0.87 0.88
CLUE 0.48 0.49 0.68 0.66
North Karelia 0.47 0.48 0.67 0.62
SIIMCHS 0.45 0.46 0.64 0.62
aThe regressed medians were constrained to have the same percentage increase in concentrations per 10 years of age for each
centre. BUPA – British United Provident Association, London, UK. CLUE – Washington County, MD, USA. North Karelia –
Finland. SIIMCHS – Social Insurance Institution Mobile Clinic Health Survey, Finland.
Table 5 Cut-off levels in multiples of the normal median (MOM)
concentrations in control men of the same age and at the same centre
corresponding to specified false-positive rates for total PSA, free PSA and
PSA-ACT measurement. Men with MOM values above the specified cut-off
level are designated screen positive. Calculation based on Gaussian
distributions of risk factors
Cut-off level
False-positive rate (%) Total PSA Free PSA PSA-ACT
5.0 4.3 4.2 4.0
2.0 6.2 6.1 5.7
1.0 7.9 7.8 7.1
0.5 9.8 9.7 8.8loss would be different, on average, between the men who devel-
oped prostate cancer and those who did not, or to expect any mate-
rial variation in proportionate loss between individuals in view of
the high correlation of free PSA with both total PSA and PSA-
ACT (r = 0.85) in our data (Figure 1). With a constant propor-
tionate loss, the ranking of samples would be preserved and
estimated detection rates for given false-positive rates would,
therefore, be unchanged.
While the performance of either total PSA or free PSA and
PSA-ACT together as a screening test for future clinical prostate
cancer is good, the value of screening for prostate cancer is
unknown because the efficacy and morbidity of treatment are
unknown. Early treatment of asymptomatic men would need to be
better than treating men once disease had been clinically diag-
nosed. Side-effects from early treatments and psychological
effects of early diagnosis would need to be balanced against any
improvements in life expectancy. Screening has already been
implemented and partially assessed in some places in the USA
(Arcangeli et al, 1997) in the absence of evidence of benefit. The
results from randomized screening trials that are underway are
needed to assess the presence of benefit (Auvinen et al, 1996).
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